Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer

Additional Information

Published Date Mar 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3380
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Pancreatic Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer.

    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
AB Science
Abbott
Abiogen
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bayer
Benitec
Betapharma
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
BioLineRx
Bionovo
BioNumerik
BioSante
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Circadian Technologies
Clavis Pharma
CLL Pharma
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CritiTech
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
Dong-A
Dr Reddy’s
Dynavax Technologies
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endocyte
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Esperance Pharmaceuticals
Exelixis
Favrille
FibroGen
Forma Therapeutics
Fresenius
Galapagos
Galectin Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Gradalis
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
Kiadis
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Pro-Pharmaceuticals
Progen Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Protgen
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
SRI International
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
Vaccinex
Valeant
Vaxon Biotech
VaxOnco
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
Wyeth
XBiotech
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zeria
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
131I-tositumomab
AEG-35156
afatinib
aflibercept
AGS-1C4D4
alemtuzumab
amrubicin hydrochloride
apricoxib
ARC-100
ARQ-197
astuprotimut-r
bardoxolone methyl
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
bexarotene
BIBF-1120
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
brivudine
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
conatumumab
CPI-613
crizotinib
CRLX-101
dacomitinib
dalotuzumab
dasatinib
denileukin diftitox
docetaxel
doxorubicin
E-7820
elliptinium acetate
emepepimut-S
endostatin
eniluracil
enzastaurin hydrochloride
epirubicin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
galiximab
ganitumab
gefitinib
GSK-1120212
GV-1001
GVAX
HBP-347
ibritumomab tiuxetan
icotinib hydrochloride
imatinib mesilate
IMP-321
iniparib
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon (gamma1b)
interferon alfa-2b
interferon alpha-2b
ipilimumab
irinotecan
irinotecan hydrochloride
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
LipoVIL12
masitinib
MetXia
mitoxantrone
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
nadroparin
necitumumab
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
OTS-102
P-276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pixantrone
plitidepsin
pralatrexate
PX-12
ramucirumab
razoxane
Reditux
Rexin-G
rhIFN-alpha
rituximab
romidepsin
RX-0201
selumetinib
siltuximab
sobuzoxane
sorafenib tosylate
ß-lapachone
sunitinib malate
talactoferrin alfa
talminogene laherparepvec
tegafur + uracil
temsirolimus
teniposide
thymalfasin
tigatuzumab
tocilizumab
topotecan
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
varlitinib
vismodegib
volociximab
WX-671
Z-360
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer.
    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Leukemia and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Pancreatic Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More